Gustave Roussy announces its Development Project 2015-2020
Gustave Roussy announces its Development Project 2015-2020
Drawing on scientific and therapeutic innovations, technological and organisational advances, and a fresh approach to the patient-hospital relationship, the Gustave Roussy development project for 2015-2020 strives to achieve the levels of excellence and innovation demanded by the fight against cancer.
Resulting from several months of work by the entire body of professionals at the Institute, the development project is structured around Gustave Roussy’s three core missions, namely care, research and teaching. It provides a framework, based on existing foundations, for a new Cancer Centre model: a centre of expertise, equipped with high technology platforms, meeting the challenges of molecular medicine and immunotherapy through its dynamic research and development of early testing techniques. In pursuit of its ambition to provide comprehensive care focussed on the individual, it will combine these cutting-edge technologies with a more customised approach, taking account of the preferences of patients and their loved ones.
Excellence and innovation in research and care
Driving scientific, technological and organisational innovations, the Institute’s research ultimately seeks to improve care, in the best interests of patients. One of Gustave Roussy’s primary missions is to offer its patients therapeutic innovation. At the Institute, the very close integration of clinical, fundamental and translational research is a vital factor in the successful transmission of innovation into care services. To further strengthen these links, major investments will enable the creation of the primary preclinical platform for cancer in Europe (PRECAN) aiming to consolidate the research-care continuum. The launch of a major immunotherapy programme and continuation of the molecular medicine programme will also constitute key strands for research and development in innovative cancer treatments.
Gustave Roussy will continue to equip its radiotherapy, interventional imaging and surgery platforms with the latest ground-breaking technologies, in order to develop the best possible care protocols. The Institute will also develop a global treatment chain in haematology.
Gustave Roussy will thus consolidate its position of expertise, ensuring that its patients gain access to innovative, latest-generation treatments. The challenge for the next five years will be to organise oncology within a regional care network around the Institute, thereby improving the quality, accessibility and pertinence of treatment.
Playing a major role at international level
The Institute aspires to strong international development, supported by structured partnerships such as the Cancer Core Europe network. Led by Gustave Roussy, this consortium already brings together 6 centres of excellence* in the fight against cancer, conducting research projects at European level. Significant investments, both intellectual and financial, will lead to the creation of the first European e-hospital.
Looking to 2020, Gustave Roussy intends to develop an international cancer research centre, firmly anchored in its local area, by creating an attractive science centre within the framework of Grand Paris and Cancer Campus, Europe’s leading oncology biopark, in southern Ile-de-France.
Development of the Institute’s academic mission, taking an international approach through specialist training programmes offered in English and French, will affirm its position as a benchmark site for oncology within the future university of Paris-Saclay.
In a sustainably sound financial context, Gustave Roussy can look to 2015-2020 in pursuit of a dynamic development strategy directly benefiting its patients.
* Gustave Roussy (Villejuif – France), Cambridge Cancer Centre (Cambridge, United Kingdom), Karolinska Institutet – KI (Stockholm, Sweden), Netherlands Cancer Institute – NKI (Amsterdam, Netherlands), Vall d’Hebron Institute of Oncology – VHIO (Barcelona, Spain), German Cancer Research Center – DKFZ and the National Center for Tumor Diseases – NCT (Heidelberg, Germany).